Affiliations 

  • 1 Faculty of Industry & Mining (Khash), University of Sistan and Baluchestan, Zahedan, Iran
  • 2 Chemistry Department, University of Sheffield, Dainton Building, Brook Hill, Sheffield, S3 7HF, UK
  • 3 Department of Human and Rehabilitation Sciences, The Begum Nusrat Bhutto Women University, Sukkur, Sindh, Pakistan
  • 4 Department of Chemistry, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, 602 105, India
  • 5 Faculty of Dentistry, Brawijaya University, Malang, Indonesia
  • 6 Microbiology Unit, Preclinical Department, Faculty of Medicine, University Kuala Lumpur, Royal College of Medicine Perak (UniKL-RCMP), Ipoh-30450, Perak, Malaysia
  • 7 Department of Chemical and Petrochemical Engineering, The College of Engineering & Architecture, Initial Campus, Birkat Al Mouz Nizwa, Oman
Heliyon, 2024 Jun 30;10(12):e32863.
PMID: 38994094 DOI: 10.1016/j.heliyon.2024.e32863

Abstract

The engineered nano-vehicle was constructed using magnetic iron oxide nanoparticles (MIONs) and chitosan (CTS) to stabilize anticancer agent vanillic acid (VNA) which was loaded on CTS-coated MIONs nanocarrier, and more importantly, to achieve sustained VNA release and subsequent proper anticancer activity. The new thermally stable VNA-CTS- MIONs nanocomposite was spherical with a middle diameter of 6 nm and had a high drug loading of about 11.8 %. The MIONs and resulting nanocomposite were composed of pure magnetite and therefore, were superparamagnetic with saturation magnetizations of 53.3 and 45.7 emu.g-1, respectively. The release profiles of VNA from VNA-CTS-MIONs nanocomposite in different pH values were sustained and showed controlled pH-responsive delivery of the loaded VNA with 89 % and 74 % percentage release within 2354 and 4046 min at pH 5 and 7.4, respectively, as well as were in accordance with the pseudo-second-order model. The VNA-CTS-MIONs nanocomposite treatment at diverse concentrations remarkably decreased the viability and promoted ROS accumulation and apoptosis in the MDA-MB-231 breast cancer cells. Hence, it can be a propitious candidate for the management of breast cancer in the future.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.